-
ICD-10-CM Codes
›
-
C00-D49
›
-
D00-D09
›
-
D09-
›
-
2023 ICD-10-CM Diagnosis Code D09.9
2023 ICD-10-CM Diagnosis Code D09.9
Carcinoma in situ, unspecified
2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
- D09.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2023 edition of ICD-10-CM D09.9 became effective on October 1, 2022.
- This is the American ICD-10-CM version of D09.9 - other international versions of ICD-10 D09.9 may differ.
The following code(s) above
D09.9 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
that may be applicable to
D09.9:
- C00-D49
2023 ICD-10-CM Range C00-D49
NeoplasmsNote- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
- D00-D09
2023 ICD-10-CM Range D00-D09
In situ neoplasmsIncludes- Bowen's disease
- erythroplasia
- grade III intraepithelial neoplasia
- Queyrat's erythroplasia
- D09
ICD-10-CM Diagnosis Code D09
Carcinoma in situ of other and unspecified sites
2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
- Adenocarcinoma in situ in villous adenoma
- Cancer in situ
- Cancer in situ in villous adenoma
- Carcinoma in situ
- Carcinoma in situ in villous adenoma
- Muir-torre syndrome
- Muir-torrè syndrome
Clinical Information
- (kar-sin-o-ma in sye-too) cancer that involves only the cells in which it began and that has not spread to neighboring tissues.
- A group of abnormal cells that remain in the place where they first formed. They have not spread. These abnormal cells may become cancer and spread into nearby normal tissue.
- A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
- A malignant epithelial neoplasm confined to the epithelial layer and without evidence of further tissue invasion.
- A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion.
ICD-10-CM D09.9 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):
- 826 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with mcc
- 827 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with cc
- 828 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures without cc/mcc
- 829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
- 830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
- 843 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with mcc
- 844 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with cc
- 845 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses without cc/mcc
Convert D09.9 to ICD-9-CM
Code History
- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
ICD-10-CM Codes Adjacent To D09.9
D09.0 Carcinoma in situ of bladder
D09.1 Carcinoma in situ of other and unspecified urinary organs
D09.10 Carcinoma in situ of unspecified urinary organ
D09.19 Carcinoma in situ of other urinary organs
D09.2 Carcinoma in situ of eye
D09.20 Carcinoma in situ of unspecified eye
D09.21 Carcinoma in situ of right eye
D09.22 Carcinoma in situ of left eye
D09.3 Carcinoma in situ of thyroid and other endocrine glands
D09.8 Carcinoma in situ of other specified sites
D09.9
Carcinoma in situ, unspecified
D10 Benign neoplasm of mouth and pharynx
D10.0 Benign neoplasm of lip
D10.1 Benign neoplasm of tongue
D10.2 Benign neoplasm of floor of mouth
D10.3 Benign neoplasm of other and unspecified parts of mouth
D10.30 Benign neoplasm of unspecified part of mouth
D10.39 Benign neoplasm of other parts of mouth
D10.4 Benign neoplasm of tonsil
D10.5 Benign neoplasm of other parts of oropharynx
D10.6 Benign neoplasm of nasopharynx
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.
